Research Insight

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes. Xigduo XR is a combination of two...

US-based drugmaker Pfizer has received accelerated approval from US Food and Drug Administration (FDA) for its Trumenba to treat Meningococcal B disease in adolescents and young adults. As part of the breakthrough therapy designation...

UK-based Hikma Pharmaceuticals has partnered with Eisai to distribute first-class epilepsy treatment Fycompa (perampanel) in the Middle East. Eisai has developed Fycompa to treat partial onset seizures, with or without secondarily generalised seizures,...

Gilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype 1 infection in adults. Obtained approval...

Merck subsidiary EMD Serono, The Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and licence agreement for new drug candidates to treat different forms of cancer. The ...

Swiss drug maker Novartis has partnered with US-based Bristol-Myers Squibb (BMS) to assess the safety, tolerability and preliminary efficacy of its three molecularly targeted compounds in combination with BMS's Opdivo (nivolumab). The investigational...

The UK Medical Research Council (MRC) has granted a fund of £6m for three new research programmes, as part of a £60m investment. The investment will be used to study biological mechanisms of Parkinson's disease and reduced...